Ifosfamide-related encephalopathy in elderly patients: Report of five cases and review of the literature

Drugs and Aging

Volumn 24, Issue 11, 2007, Pages 967-973

  Brunello, Antonella ^a   Basso, Umberto ^a   Rossi, Elena ^a   Stefani, Micaela ^a   Ghiotto, Cristina ^a   Marino, Dario ^a   Crivellari, Gino ^a   Monfardini, Silvio ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Encephalopathy, treatment; Ifosfamide, therapeutic use; Methylthioninium chloride, therapeutic use

Indexed keywords

IFOSFAMIDE; METHYLENE BLUE;

ABDOMINAL TUMOR; AGED; AGITATION; AUDITORY HALLUCINATION; BRAIN DISEASE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONFUSION; CRYING; DELIRIUM; DEPRESSION; DEPRESSIVE PSYCHOSIS; DISABILITY; DISORIENTATION; FEMALE; HUMAN; LANGUAGE DISABILITY; LUNG SMALL CELL CANCER; MALE; MENTAL INSTABILITY; MIOSIS; MULTIPLE MYELOMA; NEUROTOXICITY; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SIDE EFFECT; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; UTERUS SARCOMA; VISUAL HALLUCINATION;

EID: 36048935132     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724110-00008     Document Type: Review

References (37)

1. Kaijser GP, Beijnen JH, Bult A. Ifosfamide metabolism and pharmacokinetics. Anticancer Res 1994 Mar-Apr; 14 (2A): 517-32
2. Klastersky J. Side effects of ifosfamide. Oncology 2003; 65 Suppl. 2: 7-10
3. Cerny T, Lind M, Thatcher N, et al. A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC). Br J Cancer 1989 Aug; 60 (2): 258-61
4. Küpfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide and encephalopathy. Eur J Clin Pharmacol 1996; 50: 249-52
5. Visarius TM, Bahler H, Kupfer A, et al. Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos 1998 Mar; 26 (3): 193-6
6. Chatton JY, Idle JR, Vagbo CB, et al. Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons. J Pharmacol Exp Ther 2001 Dec; 299 (3): 1161-8
7. Kupfer A, Aeschlimann C, Wermuth B, et al. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994 Mar 26; 343 (8900): 763-4
8. Patel PN. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother 2006 Feb; 40 (2): 299-303
9. Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000 Jan; 82 (2): 291-4
10. Buesa JM, Garcia-Teijido P, Losa R, et al. Treatment of ifosfamide encephalopathy with intravenous thiamin. Clin Cancer Res 2003 Oct 1; 9 (12): 4636-7
11. Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract 2006 Dec; 12 (4): 237-9
12. Basso U, Monfardini S. Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. Eur J Cancer Care (Engl) 2004 Dec; 13 (5): 424-33
13. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Williston Park) 2000; 14: 221-7
14. Rieger C, Fiegl M, Tischer J, et al. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004 Apr; 15 (4): 347-50
15. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005 Jun; 28 (3): 277-80
16. Meanwell CA, Blake AE, Kelly KA, et al. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986 Jul; 22 (7): 815-9
17. Danesh MM, De Giorgio CM, Beydoun SR. Ifosfamide encephalopathy. J Toxicol Clin Toxicol 1989; 27 (4-5): 293-8
18. Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med 1995 May 4; 332 (18): 1239-40
19. Park IS, Lee HJ, Lee YS, et al. Ifosfamide-induced encephalopathy with or without using methylene blue. Int J Gynecol Cancer 2005 Sep-Oct; 15 (5): 807-10
20. Sarosy G. Ifosfamide: pharmacologic overview. Semin Oncol 1989 Feb; 16 (1 Suppl. 3): 2-8
21. Lewis LD, Fitzgerald DL, Mohan P. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmacol 1991 Jan; 31 (1): 77-8
22. Aeschlimann C, Cerny T, Küpfer A. Inhibition of mono(amine) oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos 1996; 24: 1336-9
23. Kaijser GP, Keize HJ, Beijnen JH, et al. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide. Anticancer Res 1996 Sep-Oct; 16 (5B): 3247-57
24. Cerny T, Castiglione M, Brunner K, et al. Ifosfamide by continuous infusion to prevent encephalopathy [letter]. Lancet 1990 Jan 20; 335 (8682): 175
25. Cain JW, Bender CM. Ifosfamide-induced neurotoxicity: associated symptoms and nursing implications. Oncol Nurs Forum 1995 May; 22 (4): 659-66
26. Gonzalez-Angulo AM, Orzano JA, Davila E. Ifosfamide-induced encephalopathy. South Med J 2002 Oct; 95 (10): 1215-7
27. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the age: the index of ADL. A standardised measure of biological and psychological function. JAMA 1963 Sep 21; 185: 914-9
28. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969 Autumn; 9 (3): 179-86
29. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 Apr; 12 (1): 189-98
30. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression rating scale: a preliminary report. J Psychiatr Res 1982-3; 17 (1): 37-49
31. Hickie C, Snowdon J. Depression scales for the elderly: GDS. Clin Gerontol 1987; 6: 51-3
32. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40 (5): 373-83
33. Linn BS, Linn MW, Gurel L. Cumulative Illness Rating Scale. J Am Geriatr Soc 1968 May; 16 (5): 622-6
34. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in gero-psychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992 Mar; 41 (3): 237-48
35. De Pas T, Curigliano G, Catania C, et al. Ifosfamide in the elderly: clinical considerations for a better drug management. Crit Rev Oncol Hematol 2000 Feb; 33 (2): 129-35
36. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004 Feb; 15 (2): 291-5
37. Ifosfamide; drug index, BC Cancer Agency cancer drug manual [online]. Available from URL: http://www.bccancer.bc.ca [Accessed 2007 Sep 13]